That distinction is where organizations encounter their greatest challenge. Negotiating the partnership is difficult. Building an enterprise that consistently delivers exceptional outcomes, seamless coordination, and operational excellence is considerably harder. Clinical pathways must be integrated. Technology must support coordinated care. Facilities must become operationally ready. Physicians and staff must adopt new ways of working together.
The organizations that distinguish themselves ask a different question. Rather than asking how to create a successful partnership, they ask how to build an oncology enterprise capable of fulfilling the partnership’s promise. What follows are the disciplines that separate the two.
Begin with a shared patient promise
Organizations rarely enter oncology partnerships simply to share costs or construct a facility. They partner because they believe that together they can accomplish something neither could achieve alone, expanding access to advanced therapies, strengthening research, improving outcomes, recruiting specialized talent.
Yet organizations often spend more time defining how they will work together than what they intend to build together. Governance structures are negotiated. Financial models are refined. Capital commitments are established. Far less time goes to defining the future state of the enterprise itself, in terms concrete enough to be tested.
The discipline here is specificity. A quantified business case built before definitive agreements are signed isn’t a justification exercise. It forces the partners to state what the venture will produce, what reaching that will cost, and what each party is committing in capital and capability. Its real value is that it surfaces disagreement while disagreement is still inexpensive. Partners who skip this step often discover late that they held materially different pictures of what they were building.
This matters more in oncology than in most service lines. Cancer care depends on coordination across multiple specialties, disciplines, and care settings. Patients experience a single journey regardless of how many organizations participate in delivering it. They rarely think about governance structures or ownership arrangements; they judge the partnership by whether their care felt coordinated.
That standard should shape the enterprise definition from the beginning. Clinical pathways aligned rather than merely compared. Multidisciplinary teams operating with shared expectations. Navigation, supportive care, survivorship, and research integrated into the patient journey rather than organized around institutional boundaries. Organizational identities remain; the care model functions as a coordinated whole.
Without that shared definition, well-structured partnerships drift toward organizational optimization rather than enterprise performance. Each decision is evaluated through the lens of the individual partner because there is no agreed enterprise to evaluate it against.
The most successful partnerships gradually shift the conversation from our organizations to our cancer program. That change in language reflects more than culture. It reflects a shared commitment made explicit enough to guide decisions.
Design governance that enables decisions
Governance is often viewed as the cornerstone of a successful partnership, and for good reason. Clear decision rights, accountability, and executive alignment provide the foundation for organizations to work together. But governance is valuable only to the extent that it enables timely, informed decisions that advance the venture. Three design choices determine whether it does.
The first is where loyalty sits. The most common governance failure in maturing joint ventures is representational governance, that is directors behaving as delegates of the organization that appointed them, when the fiduciary obligation they actually carry runs to the venture. This is the mechanism behind the pattern leaders describe as partners looking out for their own interests. It’s rarely bad faith. It’s a structure that never told directors otherwise. The correctives are well established: orienting directors explicitly to where their obligation lies, appointing independent directors who hold no interest in either parent, documenting a written authority matrix that specifies which decisions belong to the board and which are reserved to the owners, and building dispute resolution into the agreement rather than discovering its absence during a deadlock.
The second design choice is how much authority the board delegates. Decisions about physician recruitment, technology, clinical research, and program expansion often can’t wait for deliberation across multiple organizational layers. Ventures whose management must route operational matters back to both parents accumulate delay as a structural feature rather than an occasional failure. The management time spent answering owner requests creates a new level of overhead on the business. It’s the result of a board that didn’t delegate authority for the venture to act on its own. The same research finds that consensus decision-making without a mechanism to break deadlock is among the most reliable ways to slow a venture down.
The third choice is the least intuitive and the most consequential. Partners naturally negotiate exit protection, unwind provisions tied to time or financial performance that allow either party to withdraw. Those provisions are prudent in isolation. In practice, though, ease of exit and depth of integration tend to move in opposite directions. Unwind terms create uncertainty, and uncertainty discourages exactly the investments that produce value: the shared navigation team, the integrated pathway, the research infrastructure, the common technology platform. Few leaders commit capital or reputation to an operating model that either parent can dissolve. The protection is rational. The result is a venture that never fully becomes one.
A related caution applies to complexity. Highly structured governance features, such as springing powers or control that shifts on financial triggers, are often introduced to break a negotiation impasse. They frequently succeed in the short term and compromise the relationship in the long term. Where complexity beyond what the model requires is being added to work around a gating issue, the better path is usually to address the issue directly or move the negotiation to another lever, such as capital commitment.
Governance designed this way spends less time managing itself and more time improving care.
Invest in enterprise activation
For many oncology partnerships, the most visible milestone is the opening of a new or expanded cancer center. Construction is complete. Equipment is installed. The ribbon is cut. It’s tempting to view that moment as the culmination of the partnership. It is closer to the beginning.
A completed facility isn’t an operationally ready enterprise. Patients don’t experience the quality of a construction project; they experience the quality of the care delivered within it. Operational readiness extends well beyond the building. Clinical workflows must be tested. Technology platforms must function across organizations. Equipment must be commissioned and validated. Physicians and staff must understand new roles. Regulatory requirements must be satisfied. Leaders must be positioned to decide quickly as issues surface in the first weeks of operation.
These activities are often treated as implementation details delegated to the project team. The earliest days of a new program establish patterns that persist long after opening, and the cost of getting them wrong isn’t marginal. Research across joint ventures finds that mistakes made during launch can erode as much as half of a venture’s value. High-performing enterprises treat activation as an enterprise discipline rather than the final phase of a construction project.
The same principle applies to capabilities that have no building attached. Research infrastructure is the clearest example and the most instructive. Under the National Cancer Institute’s Community Cancer Centers Program, participating sites deliberately built the operation required to support trial conduct, including staffing, informatics, biospecimen collection, and outreach. Phase III trial availability at those sites rose 16% and accrual rose 133 %, against national increases of 8% and 30% over the same period. Enrollment of racial and ethnic minorities rose 82%.
Those results didn’t follow from an agreement granting access to trials. They followed from building and staffing the operation that makes access usable. That distinction is the whole of activation.
Measure the enterprise
What organizations choose to measure shapes what they improve.
Traditional metrics remain essential. Financial performance, patient volumes, market share, physician recruitment, and operating margin all bear on the sustainability of the partnership. But they measure the partners. They don’t measure the enterprise, and a venture can perform acceptably on all of them while delivering little of what it was formed to deliver.
Clinical trial access illustrates the gap precisely. Expanded access to research is among the most frequently cited justifications for academic and community oncology partnerships. National data drawn from Commission on Cancer accreditation shows enrollment to cancer treatment trials at 21.6% at NCI-designated comprehensive cancer centers, 5.7% at integrated network cancer programs, and 4.1% at community programs.
Integrated network cancer programs are the category most of these partnerships occupy. The structures are in place. The gap they were formed to close remains largely open.
That isn’t an argument against partnering. Affiliation networks can move performance. When thirteen community hospitals joined one academic affiliate network, they improved significantly on three of four Commission on Cancer quality measures and outperformed thirteen matched non-participating hospitals on three. The point is narrower and more useful. Enrollment rate is the kind of measure that reveals whether the enterprise is functioning. Volume and margin aren’t.
High-performing enterprises broaden the definition of performance accordingly. They ask whether patients are receiving timely access. Whether multidisciplinary teams function across organizational lines. Whether pathways are consistently followed. Whether research participation is expanding. Whether physicians collaborate across boundaries. Whether patients experience a coordinated journey from diagnosis through survivorship.
These are the outcomes the partnership was created to achieve, and the ones most likely to go unmeasured because no single partner owns them.
Build an enterprise that can adapt
Oncology is evolving faster than most service lines. Precision medicine continues to redefine treatment pathways. Cell and gene therapies are changing where and how care is delivered. Artificial intelligence is beginning to influence diagnosis, treatment planning, and operations. Clinical trials are becoming more decentralized.
The economics are moving as quickly as the science, and in a direction many partnership models were not built to absorb. Site-neutral payment for outpatient drug administration took effect under the calendar year 2026 Outpatient Prospective Payment System final rule, and CMS has signaled interest in extending site neutrality to additional service categories. For calendar year 2027, CMS has proposed paying for 340B-acquired drugs at average sales price minus 33.4%, an estimated $4.55 billion reduction in Medicare drug payments, offset in budget-neutral fashion by increases to non-drug outpatient payments. Medicare Part B drug price negotiation begins to affect add-on payments in 2028.
Many oncology ventures were underwritten on pro formas in which hospital outpatient drug margin and 340B spread carry a substantial share of the return. Both are compressing at once, and the offsetting dollars are moving toward services the venture’s operating model may not be organized around.
The implication is that partnerships shouldn’t be designed around a single generation of reimbursement. Governance structures, operating models, technology platforms, and clinical relationships need to be capable of evolving as the science and economics of cancer care change, which in practice means building the capacity to revisit the model deliberately rather than only when performance forces the conversation.
Adaptability has become a design requirement, not just an operational advantage.
Create true cancer programs
With the complexity of cancer care, the pace of scientific advancement, and the economic realities facing health systems, oncology partnerships will continue to grow.
But success demands more than a partnership. It requires an enterprise capable of delivering coordinated, patient-centered cancer care.
Before entering into partnership, organizations should:
- Define the enterprise concretely before designing the deal
- Build governance that can decide and that owes its allegiance to the venture
- Treat activation, measurement, and adaptability as enterprise work rather than as project milestones
The organizations that lead the next decade won’t be those that announce the most partnerships. They’ll be those that build enterprises patients experience as one coordinated cancer program.
The deal defines the relationship. The program determines the result.